ArticleJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2021
COVID-19-related cognitive dysfunction may be associated with transient disruption in the DLPFC glutamatergic pathway.
Article in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Changes in cognitive functioning after COVID-19: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Pooled it
- Metabolomics Highlights Reduced Glutamate and Acetylcarnitine in the Amniotic Fluid of Cytomegalovirus-Infected Pregnant Women.Journal of proteome research · 2026Article
- Factors associated with severe neurological sequelae of COVID-19: findings from the multicenter COVID-BRAIN imaging cohort.Frontiers in human neuroscience · 2026Article
- Review
- Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine.Current neuropharmacology · 2025Review
- Article
- Epigenetic patterns, accelerated biological aging, and enhanced epigenetic drift detected 6 months following COVID-19 infection: insights from a genome-wide DNA methylation study.Clinical epigenetics · 2024Article
- Cortical GABA Levels Are Reduced in Post-Acute COVID-19 Syndrome.Brain sciences · 2023Article
- Direct and indirect impact of SARS-CoV-2 on the brain.Human genetics · 2023Review
- The plasma metabolome of long COVID patients two years after infection.Scientific reports · 2023Article
- Brain correlates of subjective cognitive complaints in COVID-19 survivors: A multimodal magnetic resonance imaging study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2023Article
- Cognitive Deficits in the Acute Phase of COVID-19: A Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Gut-brain pathogenesis of post-acute COVID-19 neurocognitive symptoms.Frontiers in neuroscience · 2023Article
- Cognitive Impairment after Post-Acute COVID-19 Infection: A Systematic Review of the Literature.Journal of personalized medicine · 2022Review
- Is SARS-CoV-2 a Risk Factor of Bipolar Disorder?-A Narrative Review.Journal of clinical medicine · 2022Review
- New variants and new symptoms in COVID-19: First episode psychosis and Cotard's Syndrome two months after infection with the B.1.1.7 variant of coronavirus.Schizophrenia research · 2022Article
- Post-COVID-19 human memory impairment: A PRISMA-based systematic review of evidence from brain imaging studies.Frontiers in aging neuroscience · 2022Review
- Can exercise attenuate the negative effects of long COVID syndrome on brain health?Frontiers in immunology · 2022Review
- Cognitive and Neuropsychiatric Features of COVID-19 Patients After Hospital Dismission: An Italian Sample.Frontiers in psychology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment has recently attracted researchers as one of the possible neuropsychiatric manifestations of COVID-19, although how the infection perpetuates impairment of cognitive functions is still obscure. We presented a 29-year-old male patient with COVID-19 who developed new-onset transient attention deficit and memory problems following a SARS-CoV-2 infection. Structural neuroimaging was normal. MR-spectroscopy (MRS) of the bilateral DLPFC revealed significant for decreased levels of N-acetylaspartate (NAA), glutamate, and glutamate/glutamine ratio. After a follow-up without any medical treatment but with suggestions of memory exercises for three months a control MRS screening of DLPFC showed improved levels of NAA, glutamate, and glutamate/glutamine ratio. This report may suggest that cognitive deficits in SARS-CoV-2 infection can result from glutamatergic dysfunction with decreased NAA and glutamate levels in bilateral DLPFC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.